Paradigm ambulatory insulin infusion pumps - risk of hypoglycaemia
(Medtronic) Risk due to incorrect selection and delivery of bolus amount. (MDA/2014/019)
CAS deadlines
Action underway: 12 June 2014, action complete: 26 June 2014
Note: These deadlines are for staff and patients to be aware of the problem and the advice as recommended by the manufacturer in the FSN.
Device
Paradigm ambulatory insulin infusion pumps.
Manufactured by Medtronic.
Models: MMT- 511, 512, 712, 712E, 515, 715, 522, 522K, 722, 722K, 523, 523K, 723, 723K, 554, and 754.
Image of Paradigm ambulatory insulin infusion pump
Problem
Risk of hypoglycaemia due to incorrect selection and delivery of bolus amount.
Medtronic has received reports of users accidentally programming the pump to deliver the maximum bolus amount.
Action
Identify affected pumps.
Ensure that all staff and patients receive the relevant copy of Medtronic’s (FSN) dated March 2014 and follow the recommendations.
In particular:
- When programming insulin doses through the ‘Main Menu’, be aware that scrolling down allows the dose displayed on the screen to go from 0.0 units to the maximum programmed insulin dose.
- Always confirm that the insulin dose flashing on the display screen is correct before starting delivery.
- Make sure the ‘Max Bolus’ and ‘Max Basal’ settings are programmed according to individual insulin needs as determined by the healthcare professional.
Action by
- All those responsible for the use, service and maintenance of these devices
- diabetes departments.
Distribution
This MDA has been sent to
- Care Quality Commission (CQC) (headquarters) for information
- Clinical commissioning groups (CCGs)
- HSC trusts in Northern Ireland (chief executives)
- Local authorities in Scotland (equipment co-ordinators)
- NHS boards and trusts in Wales (chief executives)
- NHS boards in Scotland (equipment co-ordinators)
- NHS England area teams
- NHS trusts in England (chief executives)
Onward distribution
Please bring this notice to the attention of relevant employees in your establishment.
Below is a suggested list of recipients.
Trusts
CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:
- Clinical governance leads
- Community diabetes specialist nurses
- Community hospitals
- Diabetes clinics/outpatients
- Diabetes nurse specialists
- Diabetes, directors of
- Diabetologists
- EBME departments
- Equipment stores
- Medical directors
- Medical libraries
- Nursing executive directors
- Outpatient clinics
- Paediatric diabetes nurse specialists
- Paediatric nurse specialists
- Paediatricians
- Pharmacists
- Risk managers
- Supplies managers
NHS England area teams
CAS liaison officers for onward distribution to all relevant staff including:
- Community pharmacists
- General practitioners
Independent distribution
Establishments registered with the Care Quality Commission (CQC) (England only)
This alert should be read by:
- Clinics
- Hospitals in the independent sector
- Independent treatment centres
- Private medical practitioners
Please note: CQC and OFSTED do not distribute these alerts. Independent healthcare providers and social care providers can sign up to receive MDAs directly from the Department of Health’s Central Alerting System (CAS) by sending an email to: [email protected] and requesting this facility.
Manufacturer contact
Lezlie Bridge
Regulatory Affairs Manager, UK & Ireland
Medtronic Limited
Building 9
Croxley Green Business Park
Watford
WD18 8WW
Tel: 01923 212 213
Fax: 01923 225 273
Email: [email protected]
Feedback
If you have any comments or feedback on this Medical Device Alert please email us at: [email protected]
England
If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2014/019 or 2014/003/018/081/002.
Technical aspects
Enitan Taiwo or Elke Kerwick
Medicines & Healthcare Products Regulatory Agency
Floor 4
151 Buckingham Palace Road
London SW1W 9SZ
Tel: 020 3080 7122 / 6826
Fax: 020 8754 3965
Email: [email protected] or [email protected]
Clinical aspects
Mark Grumbridge
Medicines & Healthcare Products Regulatory Agency
Floor 4
151 Buckingham Palace Road
London SW1W 9SZ
Tel: 020 3080 7128
Fax: 020 8754 3965
Email: [email protected]
Please report via our website: Reporting adverse incidents involving medical devices
Further information about CAS can be found on the CAS website
Northern Ireland
Alerts in Northern Ireland will continue to be distributed via the NI SABS system.
Enquiries and adverse incident reports in Northern Ireland should be addressed to:
Northern Ireland Adverse Incident Centre
Health Estates Investment Group
Room 17
Annex 6
Castle Buildings
Stormont Estate
Dundonald BT4 3SQ
Tel: 02890 523 704
Fax: 02890 523 900
Email: [email protected]
http://www.dhsspsni.gov.uk/index/hea/niaic.htm
How to report adverse incidents in Northern Ireland
Please report directly to NIAIC, further information can be found on the NIAIC website
Further information about SABS can be found on the SABS website
Scotland
All requests regarding return, replacement or modification of the devices mentioned in this alert should be directed to the relevant supplier or manufacturer.
Other enquiries and adverse incident reports in Scotland should be addressed to:
Incident Reporting and Investigation Centre
NHS National Services Scotland
Gyle Square
1 South Gyle Crescent
Edinburgh EH12 9EB
Tel: 0131 275 7575
Fax: 0131 314 0722
Email: [email protected]
Incident Reporting and Investigation Centre
Wales
Enquiries in Wales should be addressed to:
Improving Patient Safety Team
Medical Directorate
Welsh Government
Cathays Park
Cardiff CF10 3NQ
Email: [email protected]
Download documents